Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.

Veure altres versions (1)

Benzodiazepines are psychoactive drugs with anxiolytic, sedative, skeletal muscle relaxant and amnestic properties. Recently triazolo-benzodiazepines have been also described as potent and highly selective protein interaction inhibitors of bromodomain and extra-terminal (BET) proteins, a family of t...

Descripció completa

Dades bibliogràfiques
Autors principals:	Filippakopoulos, P, Picaud, S, Fedorov, O, Keller, M, Wrobel, M, Morgenstern, O, Bracher, F, Knapp, S
Format:	Journal article
Idioma:	English
Publicat:	2012

Ítems similars

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
per: Filippakopoulos, P, et al.
Publicat: (2012)

The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
per: Hay, D, et al.
Publicat: (2013)

Chemical probes for bromodomains outside the BET family
per: Brennan, P, et al.
Publicat: (2013)

Developing chemical probes for the BET bromodomains
per: Hewings, D, et al.
Publicat: (2012)

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
per: Picaud, S, et al.
Publicat: (2013)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
per: Picaud, S, et al.
Publicat: (2013)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
per: Picaud, S, et al.
Publicat: (2013)

Selective inhibition of BET bromodomains.
per: Filippakopoulos, P, et al.
Publicat: (2010)

Selective inhibition of BET bromodomains.
per: Filippakopoulos, P, et al.
Publicat: (2010)

Stimulation of Hepatic Apolipoprotein A-I Production by Novel Thieno-Triazolodiazepines: Roles of the Classical Benzodiazepine Receptor, PAF Receptor, and Bromodomain Binding.
per: Kempen, H, et al.
Publicat: (2013)

Discovery of BET bromodomain inhibitors and their role in target validation
per: Mueller, S, et al.
Publicat: (2014)

Synthesis and biological investigation of (+)-JD1, an organometallic BET bromodomain inhibitor
per: Hassell-Hart, S, et al.
Publicat: (2019)

Interactome rewiring following pharmacological targeting of BET bromodomains
per: Lambert, J-P, et al.
Publicat: (2018)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
per: Philpott, M, et al.
Publicat: (2011)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
per: Philpott, M, et al.
Publicat: (2011)

Chemical probes and inhibitors of bromodomains outside the BET family
per: Moustakim, M, et al.
Publicat: (2016)

Evaluation of linker length effects on a BET bromodomain probe
per: Traquete, R, et al.
Publicat: (2019)

Promiscuous targeting of bromodomains by Bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia
per: Picaud, S, et al.
Publicat: (2016)

Bromodomains as therapeutic targets.
per: Muller, S, et al.
Publicat: (2011)

Small-molecule bromodomain inhibitors for cancer therapy
per: Qi, J, et al.
Publicat: (2010)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
per: Ciceri, P, et al.
Publicat: (2014)

Targeting bromodomains: epigenetic readers of lysine acetylation.
per: Filippakopoulos, P, et al.
Publicat: (2014)

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
per: Cheng, Z, et al.
Publicat: (2013)

Inhibition of BET bromodomain targets genetically diverse glioblastoma.
per: Cheng, Z, et al.
Publicat: (2013)

Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
per: Ciceri, P, et al.
Publicat: (2014)

Effect of BET missense mutations on bromodomain function, inhibitor binding and stability
per: Lori, L, et al.
Publicat: (2016)

Development of selective CBP/P300 benzoxazepine bromodomain inhibitors
per: Popp, T, et al.
Publicat: (2016)

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
per: Laura Lori, et al.
Publicat: (2016-01-01)

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability
per: Jennings, L, et al.
Publicat: (2018)

[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
per: Fedorov, O, et al.
Publicat: (2014)

The bromodomain interaction module.
per: Filippakopoulos, P, et al.
Publicat: (2012)

The bromodomain interaction module
per: Filippakopoulos, P, et al.
Publicat: (2012)

Developing small molecule inhibitors of the CREBBP bromodomain-histone interaction
per: Rooney, T, et al.
Publicat: (2012)

3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
per: Hewings, D, et al.
Publicat: (2011)

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
per: Chaidos, A, et al.
Publicat: (2014)

Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1
per: Meropi Bagka, et al.
Publicat: (2023-07-01)

3,5-Dimethylisoxazoles inhibit the bromodomain-histone protein-protein interaction
per: Hewings, D, et al.
Publicat: (2012)

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
per: Alison M. Kurimchak, et al.
Publicat: (2016-08-01)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
per: Kenneth K. W. To, et al.
Publicat: (2023-03-01)

3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands
per: Hewings, D, et al.
Publicat: (2011)